GLP-1-话题@MedSci

#GLP-1#

114篇内容 | 4110人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1422753, encodeId=62261422e5327, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, objectType=article, longId=198242, objectId=909a19824200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909a19824200, replyNumber=0, likeNumber=68, createdTime=2020-07-30, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909a19824200, moduleTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909a19824200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422752, encodeId=24f81422e52b4, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, objectType=article, longId=196867, objectId=4cbc19686e58, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cbc19686e58, replyNumber=0, likeNumber=92, createdTime=2020-07-02, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cbc19686e58, moduleTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cbc19686e58)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422751, encodeId=dc841422e51e8, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, objectType=article, longId=194661, objectId=5fd5194661ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd5194661ef, replyNumber=0, likeNumber=96, createdTime=2020-05-25, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd5194661ef, moduleTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd5194661ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422750, encodeId=3d641422e50c1, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=63, createdTime=2020-05-19, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422749, encodeId=b7d51422e49c6, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, objectType=article, longId=193810, objectId=97c7193810df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c7193810df, replyNumber=0, likeNumber=58, createdTime=2020-05-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c7193810df, moduleTitle=诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c7193810df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422748, encodeId=ca111422e4858, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, objectType=article, longId=191603, objectId=16ab191603bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ab191603bc, replyNumber=0, likeNumber=72, createdTime=2020-04-08, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ab191603bc, moduleTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ab191603bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422747, encodeId=808c1422e4750, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet：从临床试验到临床实践，看真实世界中GLP-1RA的心血管获, objectType=article, longId=191128, objectId=316219112851, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=316219112851, replyNumber=0, likeNumber=78, createdTime=2020-04-01, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=316219112851, moduleTitle=Lancet：从临床试验到临床实践，看真实世界中GLP-1RA的心血管获, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=316219112851)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422746, encodeId=d7f11422e46c9, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, objectType=article, longId=189905, objectId=801b18990536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801b18990536, replyNumber=0, likeNumber=69, createdTime=2020-03-14, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801b18990536, moduleTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801b18990536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422745, encodeId=0c3e1422e4546, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Stroke：GLP-1 RA可降低非致死性卒中风险, objectType=article, longId=188863, objectId=ee3a188863cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee3a188863cf, replyNumber=0, likeNumber=91, createdTime=2020-02-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee3a188863cf, moduleTitle=Stroke：GLP-1 RA可降低非致死性卒中风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee3a188863cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422744, encodeId=bd8d1422e447c, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, objectType=article, longId=188799, objectId=77e1188e9962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77e1188e9962, replyNumber=0, likeNumber=72, createdTime=2020-02-27, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77e1188e9962, moduleTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77e1188e9962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422743, encodeId=30ef1422e434c, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, objectType=article, longId=187289, objectId=33a518e289cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a518e289cb, replyNumber=0, likeNumber=63, createdTime=2020-02-04, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a518e289cb, moduleTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33a518e289cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422742, encodeId=1dd01422e42a8, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=FDA首次批准口服GLP-1片剂治疗2型糖尿病, objectType=article, longId=180094, objectId=9c46180094e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c46180094e0, replyNumber=0, likeNumber=60, createdTime=2019-09-28, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c46180094e0, moduleTitle=FDA首次批准口服GLP-1片剂治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c46180094e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422741, encodeId=9a821422e4187, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet Diabetes Endo：荟萃分析显示GLP-1RA可减少心血管事件, objectType=article, longId=179437, objectId=26881e943795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26881e943795, replyNumber=0, likeNumber=70, createdTime=2019-09-15, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26881e943795, moduleTitle=Lancet Diabetes Endo：荟萃分析显示GLP-1RA可减少心血管事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26881e943795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422740, encodeId=a2141422e4004, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Nutr Diabetes：小丸子有奇效，营养丸可延迟GLP-1峰值以控制饥饿, objectType=article, longId=179377, objectId=a9d11e93773b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9d11e93773b, replyNumber=0, likeNumber=73, createdTime=2019-09-14, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9d11e93773b, moduleTitle=Nutr Diabetes：小丸子有奇效，营养丸可延迟GLP-1峰值以控制饥饿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9d11e93773b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422739, encodeId=c9771422e39aa, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响, objectType=article, longId=177735, objectId=9d381e773577, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d381e773577, replyNumber=0, likeNumber=90, createdTime=2019-08-17, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d381e773577, moduleTitle=Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d381e773577)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422738, encodeId=8b2a1422e380a, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病, objectType=article, longId=176930, objectId=78571e6930a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78571e6930a3, replyNumber=0, likeNumber=46, createdTime=2019-08-06, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78571e6930a3, moduleTitle=2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78571e6930a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422737, encodeId=fc451422e3719, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性, objectType=article, longId=175060, objectId=fc3f1e5060e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3f1e5060e3, replyNumber=0, likeNumber=48, createdTime=2019-07-10, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3f1e5060e3, moduleTitle=Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3f1e5060e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422736, encodeId=2dfd1422e36c7, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, objectType=article, longId=167983, objectId=85e516e98361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e516e98361, replyNumber=0, likeNumber=108, createdTime=2019-06-12, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e516e98361, moduleTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e516e98361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422735, encodeId=7bd41422e3543, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=101, createdTime=2019-06-11, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1422734, encodeId=18401422e3454, content=<a href='/topic/show?id=54fa80e701' target=_blank style='color:#2F92EE;'>#GLP-1#</a>, objectTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, objectType=article, longId=163568, objectId=c531163568f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c531163568f7, replyNumber=0, likeNumber=61, createdTime=2019-04-05, rootId=0, userName=yibei, userId=f8f23732777, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c531163568f7, moduleTitle=DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c531163568f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GLP-1

2020-05-29

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖

2020-07-30

yibei (审核中...)

前往app查看评论内容

#GLP-1#

第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可

2020-07-02

yibei (审核中...)

前往app查看评论内容

#GLP-1#

JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕

2020-05-25

yibei (审核中...)

前往app查看评论内容

#GLP-1#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

yibei (审核中...)

前往app查看评论内容

#GLP-1#

诺和诺德的GLP-1激动剂semaglutide：非酒精性脂肪性肝炎的II期临床展现治疗潜力

2020-05-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus

2020-04-08

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet：从临床试验到临床实践，看真实世界中GLP-1RA的心血管获

2020-04-01

yibei (审核中...)

前往app查看评论内容

#GLP-1#

FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病

2020-03-14

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Stroke：GLP-1 RA可降低非致死性卒中风险

2020-02-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险

2020-02-27

yibei (审核中...)

前往app查看评论内容

#GLP-1#

欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病

2020-02-04

yibei (审核中...)

前往app查看评论内容

#GLP-1#

FDA首次批准口服GLP-1片剂治疗2型糖尿病

2019-09-28

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet Diabetes Endo：荟萃分析显示GLP-1RA可减少心血管事件

2019-09-15

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Nutr Diabetes：小丸子有奇效，营养丸可延迟GLP-1峰值以控制饥饿

2019-09-14

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Lancet Diabetes Endo：GLP-1激动剂对心血管事件、死亡率及肾脏事件的影响

2019-08-17

yibei (审核中...)

前往app查看评论内容

#GLP-1#

2019 南亚工作组共识建议：应用胰高血糖素样肽-1受体激动剂 (GLP-1 RAs)治疗2型糖尿病

2019-08-06

yibei (审核中...)

前往app查看评论内容

#GLP-1#

Diabetes Obes Metab：胰岛素和GLP-1联合治疗的长期疗效和安全性

2019-07-10

yibei (审核中...)

前往app查看评论内容

#GLP-1#

第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平

2019-06-12

yibei (审核中...)

前往app查看评论内容

#GLP-1#

第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力

2019-06-11

yibei (审核中...)

前往app查看评论内容

#GLP-1#

DIABETOLOGIA：MEDI4166，PCSK9抗体和GLP-1类似物融合分子在2型糖尿病超重或肥胖患者中研究

2019-04-05

科室
- - 订阅+
  - 更多科室
工具
服务